Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance. [electronic resource]
Producer: 20201207Description: 201-210 p. digitalISSN:- 1348-4540
- Acromegaly -- drug therapy
- Adenoma -- complications
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Hormonal -- therapeutic use
- Bromocriptine -- therapeutic use
- Cabergoline -- therapeutic use
- Chemical and Drug Induced Liver Injury -- epidemiology
- Child
- Disease Progression
- Dopamine Agonists -- therapeutic use
- Drug Therapy, Combination
- Female
- Growth Hormone-Secreting Pituitary Adenoma -- complications
- Human Growth Hormone -- analogs & derivatives
- Humans
- Hypoglycemia -- chemically induced
- Insulin-Like Growth Factor I -- metabolism
- Japan -- epidemiology
- Male
- Middle Aged
- Neurosurgical Procedures
- Octreotide -- therapeutic use
- Peptides, Cyclic -- therapeutic use
- Product Surveillance, Postmarketing
- Radiotherapy
- Receptors, Somatotropin -- antagonists & inhibitors
- Somatostatin -- analogs & derivatives
- Tumor Burden
- Young Adult
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.